<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is generally accepted to be a <z:e sem="disease" ids="C0032927" disease_type="Neoplastic Process" abbrv="">premalignant condition</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies have suggested the use of <z:chebi fb="11" ids="6872">methylene blue</z:chebi> (MB) chromoendoscopy to aid the identification of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> surveillance programs, but a recent study has raised the concern that MB might induce oxidative damage of DNA </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: The aim of this study was to compare MB directed biopsies (MBDB) with our current standard, which is random 4 quadrant biopsies (RB) </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: A randomized prospective crossover study </plain></SENT>
<SENT sid="4" pm="."><plain>SETTING: Single center </plain></SENT>
<SENT sid="5" pm="."><plain>PATIENTS: Patients with a diagnosis of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> identified in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> within a 2-year period before entering the study </plain></SENT>
<SENT sid="6" pm="."><plain>INTERVENTIONS: Either 4 random quadrant biopsies taken every 2 cm through the length of the <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> or MBDB from unstained or heterogenously stained mucosa </plain></SENT>
<SENT sid="7" pm="."><plain>MAIN OUTCOME MEASUREMENTS: The number of patients with a diagnosis of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> by each intervention </plain></SENT>
<SENT sid="8" pm="."><plain>LIMITATIONS: Thirty-six percent of eligible patients declined the invitation to participate </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: Thirty patients completed the crossover study </plain></SENT>
<SENT sid="10" pm="."><plain>The median length of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> was 5 cm (interquartile range [IQR] 3-9 cm) </plain></SENT>
<SENT sid="11" pm="."><plain>At baseline histology, grades were as follows: 17 low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (LGD), 3 high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (HGD), and 10 no <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="12" pm="."><plain>At completion, there were 10 LGD, 8 HGD, and 12 no <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="13" pm="."><plain>Overall, <z:mpath ids='MPATH_589'>dysplasia</z:mpath> was identified in 17 of 18 patients by RB and in 9 of 18 by MBDB (McNemar test, p = 0.02) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Our study showed MBDB to be significantly less sensitive in detecting <z:mpath ids='MPATH_589'>dysplasia</z:mpath> than RB in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="15" pm="."><plain>Hence, we discourage its use during routine surveillance of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
</text></document>